Pomerantz Law Firm Investigates Allegations of Fraud at Nuvation Bio Inc.

Pomerantz LLP, a prominent law firm based in New York, has announced it is launching an investigation on behalf of investors in Nuvation Bio Inc., a biotechnology company traded on the NYSE under the ticker NUVB. The focus of this investigation is to determine whether Nuvation and its officers or directors have engaged in any forms of securities fraud or unlawful business practices that could influence the interests of its shareholders.

On March 2, 2026, Nuvation Bio released its financial results for the fourth quarter of 2025, offering detailed insights into its commercial launch of the oncology therapy, IBTROZI (taletrectinib). Alarmingly, the company disclosed during its earnings call that a significant 75% of treatment discontinuations in 2025 were witnessed among later-line patient populations. The management elaborated that patients in these later lines often opted out of the therapy more quickly and did not receive treatment for multiple quarters, which subsequently could affect short-term revenue trends negatively.

Furthermore, Nuvation reported that a substantial proportion of early patient initiations during the launch of IBTROZI occurred in the third-line or later treatment settings, further widening the gap between patient numbers beginning the treatment and the resultant revenue growth from the product.

This distressing information prompted a significant drop in the company's stock price, which fell by $1.48 per share, translating to a dramatic 25.3% decrease, thus closing at $4.36 per share on March 3, 2026.

With a legacy spanning over 85 years, Pomerantz LLP is well-known for its expertise in corporate and antitrust class litigation. The firm took shape under the leadership of Abraham L. Pomerantz, revered as a pioneer in the field of securities class actions. Today, the firm carries forward this legacy, advocating for the rights of victims of securities fraud, and corporate misconduct while recovering multimillion-dollar damages for affected class members.

The current investigation emphasizes the need for investors associated with Nuvation Bio to remain vigilant and consider their legal options if they believe they have been affected by possible discrepancies in the company’s operations or disclosures. Those who believe they may be eligible to join the class action are urged to contact Danielle Peyton at Pomerantz LLP for more information about the ongoing investigation and potential legal steps.

In conclusion, the iconic New York-based law firm is committed to safeguarding investor interests and pursuing justice against any forms of wrongdoing, ensuring a fair landscape for all shareholders involved in Nuvation Bio Inc. As developments unfold, stakeholders are encouraged to monitor this situation closely and remain informed about their rights as investors.